Meridian Bioscience

32 articles with Meridian Bioscience

• Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

  6/16/2021

  Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays.

• Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

  5/27/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET.

• Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

  5/7/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year

• 

  Pfizer Owes Massive $14.6 Billion Q1 Revenues to Vaccine Rollout

  5/4/2021

  Pfizer reported its first-quarter 2021 revenues of $14.6 billion, an impressive 42% operational growth.

• Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix

  4/28/2021

  Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays.

• Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021

  4/19/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021.

• Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay

  4/1/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s new Curian ® Campy assay. This assay is one of many assays in the pipeline that expands the Curian ® menu, continuing Meridian’s leadership in the gastrointestinal disease and lateral flow testing mar

• Meridian Launches its New Air-Dryable Mix for Crude Blood Samples

  3/8/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, serum or plasma.

• Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal

  2/23/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform.

• Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission

  2/16/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform.

• Meridian Bioscience Reports Record Setting First Quarter Fiscal 2021 Operating Results and Raises Full Year Fiscal 2021 Guidance

  2/5/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020.

• Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown

  2/3/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.

• Meridian Bioscience to Hold First Quarter Fiscal 2021 Financial Results Conference Call on February 5, 2021

  1/13/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.

• Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results

  1/7/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021.

• Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

  1/6/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021. Jack Kenny will also be participating in a panel discussion hosted by former FDA Commissioner Scott Gottlieb, M.D. on Tuesday, J

• Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2

  12/16/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

• Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

  12/8/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene ® platform. The SARS-CoV-2 test is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the

• Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

  12/3/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed for air-drying, a cost-effective and easier alternative to lyophilization. With this new product addition, Meridian has th

• Meridian Bioscience Participates in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020. To register for access to the pre-recorded fireside chat, go to the Events & Presentations section of the Company’s Investor Relations w

• Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum

  11/16/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020